Phosphorylated KDR expression in endometrial cancer cells relates to HIF1α/VEGF pathway and unfavourable prognosis
about
The -271 G>A polymorphism of kinase insert domain-containing receptor gene regulates its transcription level in patients with non-small cell lung cancer.Molecular characterization of EGFR, PDGFRA and VEGFR2 in cervical adenosquamous carcinoma.VEGF targets the tumour cell.Active angiogenesis in metastatic renal cell carcinoma predicts clinical benefit to sunitinib-based therapy.Targeted inhibition of VEGF receptor 2: an update on ramucirumab.A phase II evaluation of pazopanib in the treatment of recurrent or persistent carcinosarcoma of the uterus: a gynecologic oncology group studyPhase II evaluation of dalantercept, a soluble recombinant activin receptor-like kinase 1 (ALK1) receptor fusion protein, for the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study 0229NVascular endothelial growth factor pharmacogenetics: a new perspective for anti-angiogenic therapy.Phase I dose escalation study of telatinib (BAY 57-9352) in patients with advanced solid tumours.Targeting of VEGF-dependent transendothelial migration of cancer cells by bevacizumab.Tyrosine kinase inhibitor sunitinib therapy is effective in the treatment of bone metastasis from cancer of unknown primary: Identification of clinical and immunohistochemical biomarkers predicting survival.Pathway enrichment analysis approach based on topological structure and updated annotation of pathway.Molecular profiling and sequential somatic mutation shift in hypermutator tumours harbouring POLE mutations.
P2860
Q33444299-2F0F13F8-81B0-4C37-8875-272C8AE4D21BQ33475963-A4B7092D-5881-487E-91D8-C6365E1431DDQ33573324-DD8B0E4C-9440-48D8-B599-E2778C04AB0AQ33682981-2D8B0040-4080-4D8A-A293-3B53ED9248F0Q34040956-3D55ECF7-E96E-454F-9C5E-26AAC013470FQ35180428-16352299-EAA6-48AD-B0AB-5E02F439BBBDQ36191443-D5061BC1-3406-444A-8948-55AB74CD572DQ36691776-6A1DB7BC-457A-4BE9-8497-3F73E272F9A7Q36977529-F8DAFC2D-FA08-4028-9524-C518433D3801Q39747275-2EBE9889-5D1F-4622-B411-DBD95256984BQ40761584-E33E0E17-6369-4C91-A609-F637CF149887Q47884625-7628EAAD-9A27-4D93-8570-D4CABB3545F5Q55448998-603CC13F-56FC-4A7D-BB90-F157B84277FC
P2860
Phosphorylated KDR expression in endometrial cancer cells relates to HIF1α/VEGF pathway and unfavourable prognosis
description
wetenschappelijk artikel
@nl
наукова стаття, опублікована в березні 2006
@uk
name
Phosphorylated KDR expression ...... way and unfavourable prognosis
@en
Phosphorylated KDR expression ...... way and unfavourable prognosis
@nl
type
label
Phosphorylated KDR expression ...... way and unfavourable prognosis
@en
Phosphorylated KDR expression ...... way and unfavourable prognosis
@nl
prefLabel
Phosphorylated KDR expression ...... way and unfavourable prognosis
@en
Phosphorylated KDR expression ...... way and unfavourable prognosis
@nl
P2093
P2860
P1433
P1476
Phosphorylated KDR expression ...... way and unfavourable prognosis
@en
P2093
Alexandra Giatromanolaki
Efthimios Sivridis
Helen Turley
Kevin C Gatter
Michael I Koukourakis
P2860
P2888
P304
P356
10.1038/MODPATHOL.3800579
P577
2006-03-24T00:00:00Z